Edition:
United States

Bill Berkrot

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Sep 13 2017

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Sep 10 2017

Lilly takes on Pfizer, Novartis with new breast cancer drug data

NEW YORK/MADRID Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.

Sep 09 2017

Lilly drug cuts risk of advanced breast cancer progression -study

Sept 9 An experimental Eli Lilly and Co drug taken with standard therapy reduced the risk of disease progression by 46 percent versus standard therapy alone in women not previously treated for advanced breast cancer, according to interim data from a late stage study presented at a medical meeting.

Sep 07 2017

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.

Aug 30 2017

Novartis gene therapy approval signals new cancer treatment era

Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers.

Aug 03 2017

PerkinElmer profit meets Street view, boosts 2017 forecast range

Scientific instruments maker PerkinElmer Inc on Thursday posted a second-quarter profit that matched expectations and boosted its full-year earnings forecast range with a new midpoint slightly ahead of Wall Street estimates.

Aug 01 2017

Pfizer delays major M&A as it awaits U.S. tax reform clarity

Pfizer Inc's chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target's value. | Video

Jul 31 2017

Express Scripts to cover Mylan's EpiPen, exclude rivals

NEW YORK Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

Jul 27 2017

Amgen gets fast FDA review for adding heart benefits to cholesterol drug label

Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

Jul 27 2017

Revlimid drives Celgene profit beat; raises EPS forecast

Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary